Phanichyakarn P, Wong E C
J Med Assoc Thai. 1989 Jan;72 Suppl 1:76-80.
Thirteen children with chronic bronchial asthma, 8 boys and 5 girls, aged between 5 and 15 (mean 10) years, with a duration of asthma ranging from 1 to 12 (mean 6) years, were studied by a control, oral prednisolone 5 mg twice a day and inhaled budesonide 100 micrograms twice daily, each for 3 weeks. The clinical efficacy assessed daily by day and night symptom scores, cough, limitation of activity and inhaled terbutaline used, showed improvement of the parameters measured during budesonide and prednisolone treatment period but did not reach statistical significance except for the night symptom scores (p less than 0.05) between the control and inhaled budesonide period and the cough between the control and oral prednisolone period. Slight improvement in pulmonary function was observed during budesonide and prednisolone. No changes of complete blood counts before and after inhaled budesonide were noted. No oral and pharyngeal thrush were observed in any studied period. Inhaled budesonide appears to be effective for treatment of chronic bronchial asthma but still requires long-term studies with higher dosages to be certain that its effect is better and maintained and without systemic side effects.
对13名患有慢性支气管哮喘的儿童进行了研究，其中8名男孩，5名女孩，年龄在5至15岁（平均10岁）之间，哮喘病程为1至12年（平均6年）。采用对照方法，口服泼尼松龙5毫克，每日两次，吸入布地奈德100微克，每日两次，各治疗3周。通过每日白天和夜间症状评分、咳嗽、活动受限情况以及使用的吸入特布他林来评估临床疗效，结果显示在布地奈德和泼尼松龙治疗期间所测量的参数有所改善，但除了对照期与吸入布地奈德期之间的夜间症状评分（p<0.05）以及对照期与口服泼尼松龙期之间的咳嗽外，均未达到统计学显著性。在布地奈德和泼尼松龙治疗期间观察到肺功能有轻微改善。吸入布地奈德前后全血细胞计数无变化。在任何研究期间均未观察到口腔和咽部念珠菌感染。吸入布地奈德似乎对慢性支气管哮喘有效，但仍需要进行更高剂量的长期研究，以确定其效果更好且能持续，并且无全身副作用。
